Process Analysis of Pluripotent Stem Cell Differentiation to Megakaryocytes to Make Platelets Applying European GMP

Overview

Journal NPJ Regen Med

Date 2021 May 27

PMID 34040001

Citations 7

Authors

Moyra Lawrence

Amanda Evans

Thomas Moreau

Marta Bagnati

Matthew Smart

Enas Hassan

Jahid Hasan

Monica Pianella

Julie Kerby

Cedric Ghevaert

Affiliations

Soon will be listed here.

Abstract

Quality, traceability and reproducibility are crucial factors in the reliable manufacture of cellular therapeutics, as part of the overall framework of Good Manufacturing Practice (GMP). As more and more cellular therapeutics progress towards the clinic and research protocols are adapted to comply with GMP standards, guidelines for safe and efficient adaptation have become increasingly relevant. In this paper, we describe the process analysis of megakaryocyte manufacture from induced pluripotent stem cells with a view to manufacturing in vitro platelets to European GMP for transfusion. This process analysis has allowed us an overview of the entire manufacturing process, enabling us to pinpoint the cause and severity of critical risks. Risk mitigations were then proposed for each risk, designed to be GMP compliant. These mitigations will be key in advancing this iPS-derived therapy towards the clinic and have broad applicability to other iPS-derived cellular therapeutics, many of which are currently advancing towards GMP-compliance. Taking these factors into account during protocol design could potentially save time and money, expediting the advent of safe, novel therapeutics from stem cells.

Citing Articles

Noninvasive total counting of cultured cells using a home-use scanner with a pattern sheet.

Mizuno M, Maeda Y, Sanami S, Matsuzaki T, Yoshikawa H, Ozeki N iScience. 2024; 27(3):109170.

PMID: 38405610 PMC: 10884908. DOI: 10.1016/j.isci.2024.109170.

Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy.

Chehelgerdi M, Dehkordi F, Chehelgerdi M, Kabiri H, Salehian-Dehkordi H, Abdolvand M Mol Cancer. 2023; 22(1):189.

PMID: 38017433 PMC: 10683363. DOI: 10.1186/s12943-023-01873-0.

Baffled-flow culture system enables the mass production of megakaryocytes from human embryonic stem cells by enhancing mitochondrial function.

Wu X, Zhang B, Chen K, Zhao J, Li Y, Li J Cell Prolif. 2023; 56(12):e13484.

PMID: 37088551 PMC: 10693187. DOI: 10.1111/cpr.13484.

Human iPS Cells for Clinical Applications and Cellular Products.

Lawrence M Handb Exp Pharmacol. 2023; 281:3-27.

PMID: 36964256 DOI: 10.1007/164_2023_643.

Manufacturing with pluripotent stem cells (PSConf 2021): Key issues for future research and development.

Stacey G, Cao J, Hu B, Zhou Q Cell Prolif. 2022; 55(8):e13301.

PMID: 35933704 PMC: 9357356. DOI: 10.1111/cpr.13301.

References

Sullivan S, Stacey G, Akazawa C, Aoyama N, Baptista R, Bedford P . Quality control guidelines for clinical-grade human induced pluripotent stem cell lines. Regen Med. 2018; 13(7):859-866. DOI: 10.2217/rme-2018-0095. View

Pawlowski M, Ortmann D, Bertero A, Tavares J, Pedersen R, Vallier L . Inducible and Deterministic Forward Programming of Human Pluripotent Stem Cells into Neurons, Skeletal Myocytes, and Oligodendrocytes. Stem Cell Reports. 2017; 8(4):803-812. PMC: 5390118. DOI: 10.1016/j.stemcr.2017.02.016. View

Kickler T, Kennedy S, Braine H . Alloimmunization to platelet-specific antigens on glycoproteins IIb-IIIa and Ib/IX in multiply transfused thrombocytopenic patients. Transfusion. 1990; 30(7):622-5. DOI: 10.1046/j.1537-2995.1990.30790385520.x. View

Takayama N, Nishikii H, Usui J, Tsukui H, Sawaguchi A, Hiroyama T . Generation of functional platelets from human embryonic stem cells in vitro via ES-sacs, VEGF-promoted structures that concentrate hematopoietic progenitors. Blood. 2008; 111(11):5298-306. DOI: 10.1182/blood-2007-10-117622. View

Nakamura S, Takayama N, Hirata S, Seo H, Endo H, Ochi K . Expandable megakaryocyte cell lines enable clinically applicable generation of platelets from human induced pluripotent stem cells. Cell Stem Cell. 2014; 14(4):535-48. DOI: 10.1016/j.stem.2014.01.011. View

Bluteau D, Lordier L, Di Stefano A, Chang Y, Raslova H, Debili N . Regulation of megakaryocyte maturation and platelet formation. J Thromb Haemost. 2009; 7 Suppl 1:227-34. DOI: 10.1111/j.1538-7836.2009.03398.x. View

Sullivan S, Ginty P, McMahon S, May M, Solomon S, Kurtz A . The Global Alliance for iPSC Therapies (GAiT). Stem Cell Res. 2020; 49:102036. DOI: 10.1016/j.scr.2020.102036. View

Santhosh Kumar P, Chandrasekhar C, Srikanth L, Sarma P . In vitro large scale production of megakaryocytes to functional platelets from human hematopoietic stem cells. Biochem Biophys Res Commun. 2018; 505(1):168-175. DOI: 10.1016/j.bbrc.2018.09.090. View

Thon J, Mazutis L, Wu S, Sylman J, Ehrlicher A, Machlus K . Platelet bioreactor-on-a-chip. Blood. 2015; 124(12):1857-67. PMC: 4168343. DOI: 10.1182/blood-2014-05-574913. View

10.

Kaufman R, AIRO R, Pollack S, CROSBY W . Circulating megakaryocytes and platelet release in the lung. Blood. 1965; 26(6):720-31. View

11.

Stanworth S, Navarrete C, Estcourt L, Marsh J . Platelet refractoriness--practical approaches and ongoing dilemmas in patient management. Br J Haematol. 2015; 171(3):297-305. DOI: 10.1111/bjh.13597. View

12.

Hegde S, Akbar H, Zheng Y, Cancelas J . Towards increasing shelf life and haemostatic potency of stored platelet concentrates. Curr Opin Hematol. 2018; 25(6):500-508. PMC: 6532779. DOI: 10.1097/MOH.0000000000000456. View

13.

Gaur M, Kamata T, Wang S, Moran B, Shattil S, Leavitt A . Megakaryocytes derived from human embryonic stem cells: a genetically tractable system to study megakaryocytopoiesis and integrin function. J Thromb Haemost. 2006; 4(2):436-42. DOI: 10.1111/j.1538-7836.2006.01744.x. View

14.

Thon J, Medvetz D, Karlsson S, Italiano Jr J . Road blocks in making platelets for transfusion. J Thromb Haemost. 2015; 13 Suppl 1:S55-62. PMC: 5565795. DOI: 10.1111/jth.12942. View

15.

Tung S, Parmar S, Robinson S, de Lima M, Shpall E . Ex vivo expansion of umbilical cord blood for transplantation. Best Pract Res Clin Haematol. 2010; 23(2):245-57. DOI: 10.1016/j.beha.2010.06.004. View

16.

Di Buduo C, Soprano P, Tozzi L, Marconi S, Auricchio F, Kaplan D . Modular flow chamber for engineering bone marrow architecture and function. Biomaterials. 2017; 146:60-71. PMC: 6056889. DOI: 10.1016/j.biomaterials.2017.08.006. View

17.

Shepherd J, Howard D, Waller A, Foster H, Mueller A, Moreau T . Structurally graduated collagen scaffolds applied to the ex vivo generation of platelets from human pluripotent stem cell-derived megakaryocytes: Enhancing production and purity. Biomaterials. 2018; 182:135-144. DOI: 10.1016/j.biomaterials.2018.08.019. View

18.

van den Oudenrijn S, von dem Borne A, de Haas M . Differences in megakaryocyte expansion potential between CD34(+) stem cells derived from cord blood, peripheral blood, and bone marrow from adults and children. Exp Hematol. 2000; 28(9):1054-61. DOI: 10.1016/s0301-472x(00)00517-8. View

19.

Harker L, Finch C . Thrombokinetics in man. J Clin Invest. 1969; 48(6):963-74. PMC: 322310. DOI: 10.1172/JCI106077. View

20.

Pineault N, Robert A, Cortin V, Boyer L . Ex vivo differentiation of cord blood stem cells into megakaryocytes and platelets. Methods Mol Biol. 2012; 946:205-24. DOI: 10.1007/978-1-62703-128-8_13. View